XML 30 R15.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring
6 Months Ended
Dec. 31, 2018
Restructuring and Related Activities [Abstract]  
Restructuring
9.
Restructuring 
In July 2016, the Company announced its plan to consolidate all research and development activities in its U.S. facility. Following employee consultations under local U.K. law, the Company determined to close its U.K. research facility and terminated the employment of its U.K. employees. The U.K. facility lease, set to expire on August 31, 2016, was extended through
November 30, 2016
to facilitate an orderly transition and the required restoration of the premises. A summary reconciliation of the restructuring costs is as follows (in thousands):
 
 
 
Balance at
 
 
Charged to
 
 
 
 
 
Balance at
 
 
 
June 30, 2016
 
 
Expense
 
 
Payments
 
 
June 30, 2017
 
Termination benefits
 
$
118
 
 
$
273
 
 
$
(391
)
 
$
 
Facility closure
 
 
40
 
 
 
73
 
 
 
(113
)
 
 
 
Other
 
 
29
 
 
 
126
 
 
 
(155
)
 
 
 
 
 
$
187
 
 
$
472
 
 
$
(659
)
 
$
 
 
The Company recorded approximately $472,000 of restructuring costs during fiscal 2017 to research and development expense. These costs consisted of (i) $273,000 of additional employee severance for discretionary termination benefits upon notification of the affected employees in accordance with ASC 420,
Exit or Disposal Cost Obligations
; and (ii) $199,000 of professional fees, travel and lease extension costs.
In addition, for the first quarter of fiscal 2017, the Company recorded $99,000 of non-cash stock-based compensation expense in connection with the extension, through June 30, 2017, of the exercise period for all vested stock options held by the U.K. employees at July 31, 2016 and a $133,000 credit to stock-based compensation expense to account for forfeitures of all non-vested stock options at that date.
The Company paid all of the restructuring costs associated with the plan of consolidation as of March 31, 2017.